Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

237 terminated/withdrawn out of 1662 trials

Success Rate

83.6%

-2.9% vs industry average

Late-Stage Pipeline

41%

687 trials in Phase 3/4

Results Transparency

39%

468 of 1210 completed trials have results

Key Signals

54 recruiting468 with results181 terminated56 withdrawn

Enrollment Performance

Analytics

Phase 2

454(29.8%)

Phase 3

383(25.1%)

Phase 1

316(20.7%)

Phase 4

304(19.9%)

N/A

59(3.9%)

Early Phase 1

9(0.6%)

1525Total

Phase 2(454)

Phase 3(383)

Phase 1(316)

Phase 4(304)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1662)

Showing 20 of 1662 trials

NCT03091257Phase 1Active Not Recruiting

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Role: collaborator

NCT05154487Phase 2Active Not Recruiting

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

Role: collaborator

NCT01797523Phase 2Completed

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

Role: collaborator

NCT03899155Phase 2Recruiting

Pan Tumor Rollover Study

Role: collaborator

NCT02328963Phase 4Completed

Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A

Role: collaborator

NCT07136428Phase 1Recruiting

Asciminib in HER2+ Breast Cancer Brain Metastases

Role: collaborator

NCT01217931Phase 2Active Not Recruiting

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

Role: collaborator

NCT03836040Phase 3Active Not Recruiting

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

Role: collaborator

NCT06865885Phase 4Recruiting

LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering

Role: collaborator

NCT03549442Phase 1Active Not Recruiting

Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma

Role: collaborator

NCT00942734Phase 2Completed

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Role: collaborator

NCT03085056Early Phase 1Active Not Recruiting

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

Role: collaborator

NCT00640978Phase 2Terminated

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Role: collaborator

NCT06526299Phase 2Recruiting

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

Role: collaborator

NCT00317720Phase 1Completed

Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer

Role: collaborator

NCT07676877Phase 1Not Yet Recruiting

Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma

Role: collaborator

NCT05207709Phase 3Terminated

Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

Role: collaborator

NCT01273610Phase 2Active Not Recruiting

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

Role: collaborator

NCT00201955Phase 3Completed

Study of Rebamipide Eye Drops to Treat Dry Eye

Role: collaborator

NCT05180695Phase 1Active Not Recruiting

HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas

Role: collaborator